Fast Facts


Five Points of Consideration for Investing in QHSLab, Inc.

At QHSLab, Inc., we shape the future of medicine through digital medicine tools that help primary care physicians improve clinical outcomes and streamline their practice workflow. We have developed a unique, cloud-based medical office, digital medicine, and virtual care platform focused on value-based healthcare solutions, clinical informatics, and reimbursable personalized medicine.

Discover why an investment made today will shape the #FutureofMedicine for generations to come.

unsplash-image-L8tWZT4CcVQ.jpg
  1. Virtual care and digital medicine came to the forefront during COVID-19 and are here to stay.

We've developed medical technologies that enable physicians to increase their revenue by providing them with value-based tools to evaluate and treat chronic disease through reimbursable, point-of-care, Software as a Service procedure.

COVID-19 has accelerated physician and patient acceptance of virtual care technologies, and demand for these solutions will continue to rise even after COVID vaccines make their way through the population.

We provide solutions to the person that patients trust the most – their primary care physician.

unsplash-image-FVh_yqLR9eA.jpg

2. We focus on independent physicians, not large hospital networks or health systems.

In today's world, health insurance reimbursements to doctors are declining, especially in primary care. More than ever, patients demand preventive care and prefer to receive these services from their trusted primary care doctor. Until now, primary care physicians have lacked easy-to-use and reimbursable tools.

In many cases, our physician customers can easily generate over one thousand dollars per year of additional income without any new patients or changes to their existing staff levels.

unsplash-image-NFvdKIhxYlU.jpg

3. Our technology generates recurring revenue with high-profit margins.

We combine AI-enhanced, connected device technology and clinically proven digital assessments of chronic conditions and health behaviors that confront millions of people daily. The average subscription income from physician clients is ten to twenty thousand dollars per year, and that's just the beginning.

We maximize our physician acquisition costs, getting a significant return on our marketing investment. The more physicians we recruit, the more revenue we generate. For example, as few as five thousand out of the five hundred thousand potential independent physician clients create fifty plus million dollars of annual recurring revenue for QHSLab, Inc.

 
unsplash-image-hIgeoQjS_iE.jpg

4. We're addressing the most prevalent chronic conditions affecting up to 80% of physician encounters in primary care.

Heavy patient caseloads inarguably lead to physician burnout and even malpractice in worst-case scenarios.

Physicians need to maximize face-to-face patient encounters and engage their patient populations remotely and in non-face-to-face interventions that enhance patient care and satisfaction, lower healthcare costs, and improve outcomes. Our business model is focused on generating returns for our shareholders, while providing doctors with new clinical solutions to address the expanding chronic disease problems.

unsplash-image-hpjSkU2UYSU.jpg

5. Medical Technology and Digital Health companies are usually eaten up by Wall Street and the VCs, providing little opportunity for retail investors.

We're an early-stage, publicly-traded company, rather than being privately held, because we believe that the future of medicine is meant to be shared especially with the clients who utilize our products and services and physicians who want to invest in the future of medicine - their future.

An early investment in QHSLab, Inc. is an opportunity to beat the VCs and Wall Street and secure your piece of equity in this broad digital health and physician services market.

unsplash-image-unRkg2jH1j0.jpg

“USAQ is an attractive valuation. The shares appear to us inexpensive on an absolute and relative basis.”

Theodore R. O’Neill,
Research Analyst Litchfield Hills

QHSLab, Inc. (Stock Symbol USAQ) has been continually identified by Litchfield Hills Research as an "attractive" opportunity for those interested in the digital medicine space. With stocks currently trading under $1, the research group rates USAQ as a BUY with a target price of $5 per share.

The future of medicine, your future, is QHSLab, Inc.

We value the symbiotic relationships with our physician clients, and many are also shareholders of QHSLab, Inc. (USAQ). We welcome the opportunity to work with you in both of these capacities.

To learn more about physician investment opportunities, book an appointment with a member of our dedicated investor relations team and learn how you can be a part of the #FutureofMedicine.

Disclaimer: We cannot guarantee trading availability. Please contact your broker directly. We do not affiliate with or recommend any of the platforms we are traded on.